Want to see DRIO full AI Analyst Report?
DRIO Stock Chart & Stats
$7.39
-$0.32(-4.11%)
At close: 4:00 PM EDT
$7.39
-$0.32(-4.11%)
Day’s Range― - ―
52-Week Range$3.01 - $16.45
Previous Close$7.47
Volume8.71K
Average Volume (3M)38.38K
Market Cap
$36.94M
Enterprise Value$79.83M
Total Cash (Recent Filing)$14.25M
Total Debt (Recent Filing)$32.41M
Price to Earnings (P/E)5.5
Beta0.23
Next Earnings
Nov 16, 2026EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.26
Shares Outstanding9,799,481
10 Day Avg. Volume69,454
30 Day Avg. Volume38,385
Financial Highlights & Ratios
PEG Ratio-1.49
Price to Book (P/B)8.32
Price to Sales (P/S)25.26
P/FCF Ratio-21.65
Enterprise Value/Market Cap2.16
Enterprise Value/Revenue3.80
Enterprise Value/Gross Profit6.78
Enterprise Value/Ebitda-2.68
Forecast
1Y Price Target
$10.00Price Target Upside35.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.98
Revenue Forecast (FY)$21.71M
Bulls Say, Bears Say
Bulls Say
Contracted ARR PipelineThe contracted ARR base provides a visible foundation for future revenue, while the predominance of multi-condition programs may deepen account penetration and increase customer value. As implementations and enrollments progress, this pipeline could support more durable growth than relying solely on new account wins.
Margin And Cost DisciplineImproving gross margin alongside substantial expense reductions indicates better operating discipline and potentially stronger unit economics. If these gains persist as revenue converts from contracted programs, DarioHealth could reduce losses more efficiently and build a clearer path toward sustainable profitability.
Platform Expansion And Data AdvantageThe longitudinal data set and DarioIQ analytics can strengthen personalization, engagement, and retention across the platform. Expanding into GLP-1, women’s health, and sleep also broadens the addressable use cases, creating opportunities to increase recurring revenue within existing customer relationships.
Bears Say
Sharp Revenue ContractionThe steep TTM revenue decline shows that commercial momentum has not yet translated into recognized sales and materially weakens the current operating base. Even if management’s pipeline converts, rebuilding scale will take time and leaves the company exposed to execution risk during the transition.
Delayed ARR ConversionThe long interval between signing contracts and reaching full-run-rate revenue delays the financial benefit of sales activity and makes near-term results dependent on launches, enrollment, and plan calendars. This timing gap can prolong weak growth and postpone the point at which operating leverage becomes visible.
Persistent Cash Burn And LossesContinued negative operating and free cash flow means the business is not yet funding operations internally, despite moderated burn. Persistent losses can consume available resources and increase reliance on external financing before revenue growth and margin gains are sufficient to support durable cash generation.
DarioHealth News
DRIO FAQ
What was DarioHealth Corp’s price range in the past 12 months?
DarioHealth Corp lowest stock price was $3.01 and its highest was $16.45 in the past 12 months.
What is DarioHealth Corp’s market cap?
DarioHealth Corp’s market cap is $36.94M.
When is DarioHealth Corp’s upcoming earnings report date?
DarioHealth Corp’s upcoming earnings report date is Nov 16, 2026 which is in 22 days.
How were DarioHealth Corp’s earnings last quarter?
DarioHealth Corp released its earnings results on Aug 11, 2026. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$1.215 by $0.365.
Is DarioHealth Corp overvalued?
According to Wall Street analysts DarioHealth Corp’s price is currently Undervalued.
Does DarioHealth Corp pay dividends?
DarioHealth Corp does not currently pay dividends.
What is DarioHealth Corp’s EPS estimate?
DarioHealth Corp’s EPS estimate is -0.95.
How many shares outstanding does DarioHealth Corp have?
DarioHealth Corp has 9,799,481 shares outstanding.
What happened to DarioHealth Corp’s price movement after its last earnings report?
DarioHealth Corp reported an EPS of -$0.85 in its last earnings report, beating expectations of -$1.215. Following the earnings report the stock price went up 0.131%.
Which hedge fund is a major shareholder of DarioHealth Corp?
Currently, no hedge funds are holding shares in DRIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DarioHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (35.32% Upside)
$10.00 (35.32% Upside)
Blogger Sentiment
Neutral
DRIO Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $22.6M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.96%
12-Months-Change
Fundamentals
Return on Equity
104.15%
Trailing 12-Months
Asset Growth
-10.83%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
DarioHealth Corp
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
DRIO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful operational progress: stronger gross margins, disciplined expense reductions, improvement in net loss, a sizable ARR pipeline ($13.1M) that is predominantly multi-condition, a strengthened cash position (~$36.8M pro forma), and product/AI-driven commercialization (DarioIQ, GLP-1, Dario Women, Dario Sleep). The principal near-term concern is a modest decline in reported revenue due to strategic channel transitions and the multi-quarter lag between contract signings and recognized recurring revenue. Management framed these as temporary/timing issues while highlighting durable improvements in margin, efficiency, and the quality of future revenue. Overall, the positives around margin expansion, expense discipline, sales pipeline quality, AI/data advantages, and cash runway materially outweigh the near-term topline timing headwinds.View all DRIO earnings summariesDRIO Stock 12 Month Forecast
Average Price Target
$10.00
▲(35.32% Upside)
Technical Analysis
Ownership Overview
10.76% Insiders
1.20% Mutual Funds
6.23% Other Institutional Investors
80.83% Public Companies and
Individual Investors